A Phase 3 interventional study of Rivaroxaban 2.5 mg and Rivaroxaban 5 mg in Acute Coronary Syndrome, Myocardial Infarction and Myocardial Ischemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 584 sites in 43 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing rivaroxaban in Acute Coronary Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Rivaroxaban · Acute Coronary Syndrome.
Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, this one has the largest enrollment, is the only one that started in 2008, is one of 2 in phase 3, and was the 2nd registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 13 studies testing rivaroxaban in Acute Coronary Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Instituto Nacional de Cardiologia Ignacio Chavez · Sites in Mexico
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15,526 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 261 across the 13 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Johnson & Johnson has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing rivaroxaban in Acute Coronary Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
Acute coronary syndrome (ACS) is a serious and life threatening condition. Following an acute coronary syndrome event patients are at risk of important additional clinical events such as death, myocardial infarction, and stroke. Six months after patients present with an index event of ST-segment myocardial infarction, approximately 15% will either have died or had another episode of myocardial ischemia, and a similar situation exists for non-ST-segment elevation myocardial infarction/unstable angina patients. This randomized; double-blind; placebo controlled study will evaluate the efficacy and safety of rivaroxaban in addition to standard care in patients with a recent ACS. Patients will be given rivaroxaban (2.5 mg twice daily or 5 mg twice daily) or placebo (twice daily) in addition to standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
Drug: Rivaroxaban 2.5 mg · Drug: Standard of care
One 5 mg rivaroxaban tablet twice daily for up to 6 months
Drug: Rivaroxaban 5 mg · Drug: Standard of care
One placebo tablet twice daily for up to 6 months
Drug: Placebo · Drug: Standard of care
One tablet twice daily
One tablet twice daily
One placebo tablet twice daily
The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke
The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
This study, an efficacy and safety study of rivaroxaban in patients with acute coronary syndrome, was conducted between 26 November 2008 and 19 September 2011. Patients were recruited from 766 study centers located in 44 countries worldwide.
| Milestone | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| Started | 5176 | 5174 | 5176 |
| Treated/safety population | 5125 | 5115 | 5110 |
| Modified intent-to-treat population | 5113 | 5114 | 5115 |
| Completed | 4393 | 4399 | 4332 |
| Not completed | 783 | 775 | 844 |
| Withdrew: Death | 194 | 147 | 196 |
| Withdrew: Lost to follow-up | 17 | 10 | 18 |
| Withdrew: Withdrawal by subject | 405 | 448 | 441 |
| Withdrew: Other reason | 167 | 170 | 189 |
The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
| Percentage of patients | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke | 7.4 | 6.1 | 6.1 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
| Percentage of patients | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke | 7.5 | 6.3 | 6.3 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
| Percentage of patients | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery | 7.6 | 7.1 | 7.2 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
| Percentage of patients | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization | 9.4 | 8.5 | 8.2 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
| Percentage of patients | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization | 8.7 | 7.3 | 7.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1,018/5,125 (19.9%) | 140/5,125 (2.7%) |
| Rivaroxaban 2.5 mg Bid | — | 1,033/5,115 (20.2%) | 259/5,115 (5.1%) |
| Rivaroxaban 5 mg Bid | — | 1,083/5,110 (21.2%) | 341/5,110 (6.7%) |
| Event | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| Angina UnstableCardiac disorders | 100/5125 | 105/5115 | 123/5110 |
| Angina PectorisCardiac disorders | 118/5125 | 93/5115 | 106/5110 |
| Cardiac FailureCardiac disorders | 41/5125 | 56/5115 | 27/5110 |
| Non-Cardiac Chest PainGeneral disorders | 39/5125 | 36/5115 | 48/5110 |
| Chest PainGeneral disorders | 33/5125 | 47/5115 | 33/5110 |
| PneumoniaInfections and infestations | 33/5125 | 37/5115 | 33/5110 |
| Sudden DeathGeneral disorders | 36/5125 | 23/5115 | 29/5110 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 11/5125 | 18/5115 | 32/5110 |
| Atrial FibrillationCardiac disorders | 27/5125 | 27/5115 | 21/5110 |
| Coronary Artery DiseaseCardiac disorders | 16/5125 | 26/5115 | 13/5110 |
| Event | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 140/5125 | 259/5115 | 341/5110 |
| Age, Categorical(Participants) | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3320 | 3239 | 3210 | 9769 |
| >=65 years | 1805 | 1876 | 1900 | 5581 |
| Age, Continuous(years) | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid | Total |
|---|---|---|---|---|
| Mean | 61.5 ± 9.38 | 61.8 ± 9.22 | 61.9 ± 9.00 | 61.7 ± 9.20 |
| Sex: Female, Male(Participants) | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid | Total |
|---|---|---|---|---|
| Female | 1280 | 1283 | 1316 | 3879 |
| Male | 3845 | 3832 | 3794 | 11471 |
| Region of Enrollment(participants) | Placebo | Rivaroxaban 2.5 mg Bid | Rivaroxaban 5 mg Bid | Total |
|---|---|---|---|---|
| Argentina | 118 | 126 | 158 | 402 |
| Australia | 172 | 182 | 150 | 504 |
| Belgium | 59 | 57 | 53 | 169 |
| Brazil | 184 | 171 | 168 | 523 |
| Bulgaria | 258 | 264 | 268 | 790 |
| Canada | 67 | 58 | 63 | 188 |
| Chile | 67 | 65 | 78 | 210 |
| China | 281 | 299 | 302 | 882 |
| Colombia | 97 | 84 | 87 | 268 |
| Croatia | 21 | 19 | 22 | 62 |
| Czech Republic | 154 | 158 | 170 | 482 |
| Denmark | 35 | 21 | 41 | 97 |
| Egypt | 63 | 47 | 46 | 156 |
| France | 68 | 67 | 72 | 207 |
| Germany | 101 | 96 | 122 | 319 |
| Greece | 19 | 21 | 27 | 67 |
| Hungary | 147 | 142 | 122 | 411 |
| India | 479 | 507 | 473 | 1459 |
| Israel | 114 | 122 | 101 | 337 |
| Italy | 78 | 77 | 77 | 232 |
| Japan | 131 | 135 | 131 | 397 |
| Latvia | 27 | 33 | 40 | 100 |
| Lithuania | 59 | 51 | 66 | 176 |
| Malaysia | 36 | 33 | 26 | 95 |
| Mexico | 71 | 96 | 86 | 253 |
| Morocco | 12 | 22 | 22 | 56 |
| Netherlands | 131 | 113 | 124 | 368 |
| New Zealand | 28 | 31 | 38 | 97 |
| Philippines | 19 | 11 | 8 | 38 |
| Poland | 332 | 361 | 356 | 1049 |
| Portugal | 36 | 36 | 43 | 115 |
| Romania | 103 | 94 | 107 | 304 |
| Russian Federation | 586 | 596 | 569 | 1751 |
| Serbia | 43 | 45 | 29 | 117 |
| Slovakia | 67 | 58 | 53 | 178 |
| South Korea | 57 | 40 | 49 | 146 |
| Spain | 71 | 73 | 76 | 220 |
| Sweden | 58 | 41 | 44 | 143 |
| Thailand | 52 | 50 | 38 | 140 |
| Tunisia | 60 | 62 | 52 | 174 |
| Turkey | 37 | 39 | 41 | 117 |
| Ukraine | 205 | 210 | 213 | 628 |
| United Kingdom | 79 | 91 | 75 | 245 |
| United States | 243 | 211 | 224 | 678 |
Showing the first 100 of 584 sites across 43 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2008, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 9 months after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →